Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030
ORION CORPORATION PRESS RELEASE 21 MARCH 2025 at 13:00 EET
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels Provides 23andMe+ Premium members with highly requested insight into their likelihood of developing slightly elevated homocysteine levels
View post:
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time
Read more:
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
OXB honoured at 2025 CDMO Leadership Awards in ‘Cell & Gene Therapy – Global’ category
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
Excerpt from:
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
SUNNYVALE, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2024 on Wednesday, March 26, 2025, and will host a corporate update conference call on Monday, March 31, 2025 (time and dial-information to be announced). The conference call will follow the presentation, “A Double-blind, Randomized Controlled Trial of an Autologous Cell Therapy in Patients with HFrEF: Principal Results from the CardiAMP-HF Trial,” at the American College of Cardiology 2025 Scientific Sessions in Chicago on March 30, 2025.
More here:
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to the University of Washington, USA. This continues the fulfillment of orders from important human research studies in the United States that have chosen to use Phamala’s pharmaceutical grade LaNeo™ MDMA capsules for their clinical research.
View original post here:
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Additional approximately $21 million tied to data release for the Company’s BEST1 program Additional approximately $21 million tied to data release for the Company’s BEST1 program
See the original post:
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the “RSA” Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution.
See the original post here:
Bright Green Corporation Announces the next steps for the completion of its restructuring plan
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD), a condition affecting over 28 million adults in the U.S. alone.
See the original post:
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place March 20-22, 2025 in Washington, D.C.
Read more here:
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX